detail content area
Stroke, 2019. 50, 1184-1192, DOI: https://doi.org/10.1161/STROKEAHA.119.024786
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke: A Retrospective Analysis of the Nationwide Multicenter Stroke Registry
Dohoung Kim, Jong-Moo Park;Kyusik Kang;Yong-Jin Cho;Keun-Sik Hong;Kyung Bok Lee;Tai Hwan Park;Soo Joo Lee;Jae Guk Kim;Moon-Ku Han;Beom Joon Kim;Jun Lee;Jae-Kwan Cha;Dae-Hyun Kim;Hyun-Wook Nah;Dong-Eog Kim;Wi-Sun Ryu;Joon-Tae Kim;Kang-Ho Choi;Jay Chol Choi;Byung-Chul Lee;Kyung-Ho Yu;Mi Sun Oh;Wook-Joo Kim;Jee-Hyun Kwon;Dong-Ick Shin;Sung-Il Sohn;Jeong-Ho Hong;Ji Sung Lee;Juneyoung Lee;Philip B. Gorelick;MPH; Hee-Joon Bae;on behalf of Clinical Research Collaboration for Stroke in Korea (CRCS-K) Investigators
Background and Purpose
Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dualantiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events. There is apaucity of data, however, on the efficacy or effectiveness of such an approach in the treatment of stroke patients withsymptomatic large artery atherosclerotic occlusive disease.
We used a multicenter stroke registry database (Clinical Research Collaboration for Stroke in Korea) to analyzeacute ischemic stroke patients due to large artery atherosclerotic occlusive disease who were treated with aspirin alone orcombination of clopidogrel and aspirin from May 2008 to May 2015. The results were analyzed by intention-to-treat, perprotocol,and as-treated methodologies. The primary end point was the 1-year composite outcome of stroke recurrence,myocardial infarction, and all-cause death. To balance the differences between groups, a frailty model using propensityscores and inverse probability of treatment weighting was used.
A total of 5934 patients with symptomatic large artery atherosclerotic occlusive disease were treated either with clopidogrel plus aspirin (n=2903, 49%) or aspirin (n=3031, 51%). The frequency of the primary outcome was 12%(n=353) in the clopidogrel-aspirin group and 14% (n=410) in the aspirin group. The hazards of the primary outcome withcombination over aspirin only were significantly reduced in the per-protocol and as-treated analyses (hazard ratio, 0.71;95% CI, 0.57–0.88; P=0.002 and hazard ratio, 0.81; 95% CI, 0.69–0.96; P=0.02, respectively), but there was borderlinesignificance in the intention-to-treat analysis (hazard ratio, 0.86; 95% CI, 0.74–1.01; P=0.06). Combination therapy wasbeneficial for all-cause death in all analyses but did not reduce recurrent stroke.
Compared with patients receiving aspirin monotherapy, the primary outcome seemed to occur less frequently in patients receiving dual antiplatelet therapy, which is explained mainly by the decrease of all-cause death. Since this is a nonrandomized, retrospective, observational study, our study should be cautiously interpreted.
- DOI: https://doi.org/10.1161/STROKEAHA.119.024786
- ISBN or ISSN: 0039-2499
- 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
- This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.